Press release: dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in nejm

Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in nejm majority of patients in this age group with eosinophilic esophagitis receiving dupixent achieved histologic remission, with improvements sustained up to one year dupixent is the first-and-only medicine indicated for eosinophilic esophagitis in the us for this age group paris and tarrytown, ny, june 26, 2024. the new england journal of medicine has published results from a positive phase 3 study of dupixent (dupilumab) in children aged one to 11 years with eosinophilic esophagitis (eoe).
REGN Ratings Summary
REGN Quant Ranking